PMID- 31086661
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201001
IS  - 2049-9434 (Print)
IS  - 2049-9442 (Electronic)
IS  - 2049-9434 (Linking)
VI  - 10
IP  - 5
DP  - 2019 May
TI  - Evaluation of symptomatic reflux esophagitis in proton pump inhibitor users.
PG  - 277-282
LID - 10.3892/br.2019.1206 [doi]
AB  - The aim of the present study was to evaluate symptomatic reflux esophagitis (RE) 
      in proton pump inhibitor (PPI) users. The present study conducted a 
      hospital-based, retrospective cross-sectional study of consecutive RE cases in 
      PPI users at Juntendo University Hospital recruited between 2008 and 2016. 
      Eligible patients were PPI users with a complete patient profile, who completed 
      the Frequency Scale for the Symptoms of Gastroesophageal Reflux Disease (FSSG) 
      questionnaire, and who underwent upper gastrointestinal endoscopy for the 
      examination of RE, hiatal hernia (HH) and endoscopic gastric mucosal atrophy 
      (EGA). The patients with RE who were administered PPIs were divided into two 
      groups: Those with symptomatic RE (FSSG>/=8) and those with non-symptomatic RE 
      (FSSG<8). The present study investigated the risk factors for symptomatic RE 
      among the patients with RE patients who were administered PPIs. Of the 13,052 
      cases who underwent patient profiling, the FSSG questionnaire and upper 
      gastrointestinal endoscopy, a total of 2,444 PPI users were eligible. Of the PPI 
      users, 206 cases (8.4%) had RE. Among the 206 patients with RE, 115 (55.8%) had 
      symptomatic RE. The profile of the symptomatic and non-symptomatic RE groups were 
      as follows: A total of 45 females (39.1%) vs. 32 females (35.2%; 
      non-significant); mean +/- standard deviation age, 54.8+/-13.5 vs. 62.9+/-11.1 years 
      (P<0.01); mean body mass index, 23.5+/-3.3 vs. 23.2+/-3.8 (non-significant); severe 
      RE, 12 (10.4%) vs. 2 (2.2%; P<0.05); HH, 70 (60.9%) vs. 40 (44.0%; P<0.05); and 
      mean score of EGA, 1.2+/-1.8 vs. 1.8+/-2.1 (P<0.05). Multivariate analysis revealed 
      that a younger age [odds ratio (OR)=0.94; 95% confidence interval (CI): 
      0.92-0.97, P<0.01] and HH(+) (OR=2.37; 95% CI: 1.30-4.34, P<0.01) were associated 
      with symptomatic RE among patients with RE who were administered PPIs. In 
      conclusion, a younger age and HH were associated with symptomatic RE in patients 
      with RE who were administered PPIs.
FAU - Asaoka, Daisuke
AU  - Asaoka D
AD  - Department of Gastroenterology, University of Juntendo, School of Medicine, Tokyo 
      113-8421, Japan.
FAU - Takeda, Tsutomu
AU  - Takeda T
AD  - Department of Gastroenterology, University of Juntendo, School of Medicine, Tokyo 
      113-8421, Japan.
FAU - Sasaki, Hitoshi
AU  - Sasaki H
AD  - Department of Gastroenterology, Juntendo Tokyo Koto Geriatric Medical Center, 
      Tokyo 136-0075, Japan.
FAU - Shimada, Yuji
AU  - Shimada Y
AD  - Department of Gastroenterology, Juntendo University Shizuoka Hospital, Shizuoka 
      410-2211, Japan.
FAU - Matsumoto, Kenshi
AU  - Matsumoto K
AD  - Department of Gastroenterology, University of Juntendo, School of Medicine, Tokyo 
      113-8421, Japan.
FAU - Ueyama, Hiroya
AU  - Ueyama H
AD  - Department of Gastroenterology, University of Juntendo, School of Medicine, Tokyo 
      113-8421, Japan.
FAU - Matsumoto, Kohei
AU  - Matsumoto K
AD  - Department of Gastroenterology, University of Juntendo, School of Medicine, Tokyo 
      113-8421, Japan.
FAU - Izumi, Kentaro
AU  - Izumi K
AD  - Department of Gastroenterology, University of Juntendo, School of Medicine, Tokyo 
      113-8421, Japan.
FAU - Komori, Hiroyuki
AU  - Komori H
AD  - Department of Gastroenterology, University of Juntendo, School of Medicine, Tokyo 
      113-8421, Japan.
FAU - Akazawa, Yoichi
AU  - Akazawa Y
AD  - Department of Gastroenterology, University of Juntendo, School of Medicine, Tokyo 
      113-8421, Japan.
FAU - Osada, Taro
AU  - Osada T
AD  - Department of Gastroenterology, Juntendo University Urayasu Hospital, Chiba 
      279-0021, Japan.
FAU - Hojo, Mariko
AU  - Hojo M
AD  - Department of Gastroenterology, University of Juntendo, School of Medicine, Tokyo 
      113-8421, Japan.
FAU - Nagahara, Akihito
AU  - Nagahara A
AD  - Department of Gastroenterology, University of Juntendo, School of Medicine, Tokyo 
      113-8421, Japan.
LA  - eng
PT  - Journal Article
DEP - 20190409
PL  - England
TA  - Biomed Rep
JT  - Biomedical reports
JID - 101613227
PMC - PMC6489533
OTO - NOTNLM
OT  - Frequency Scale for the Symptoms of Gastroesophageal Reflux Disease
OT  - gastro-esophageal reflux disease
OT  - potassium-competitive acid blocker
OT  - proton pump inhibitor
OT  - reflux esophagitis
OT  - symptomatic reflux esophagitis
EDAT- 2019/05/16 06:00
MHDA- 2019/05/16 06:01
PMCR- 2019/04/09
CRDT- 2019/05/16 06:00
PHST- 2018/12/12 00:00 [received]
PHST- 2019/04/05 00:00 [accepted]
PHST- 2019/05/16 06:00 [entrez]
PHST- 2019/05/16 06:00 [pubmed]
PHST- 2019/05/16 06:01 [medline]
PHST- 2019/04/09 00:00 [pmc-release]
AID - BR-0-0-1206 [pii]
AID - 10.3892/br.2019.1206 [doi]
PST - ppublish
SO  - Biomed Rep. 2019 May;10(5):277-282. doi: 10.3892/br.2019.1206. Epub 2019 Apr 9.